Beryl Drugs Limited (BOM:524606)

Beryl Drugs Statistics

Total Valuation

Beryl Drugs has a market cap or net worth of INR 112.85 million. The enterprise value is 155.19 million.

Market Cap	112.85M
Enterprise Value	155.19M

Important Dates

The next estimated earnings date is Friday, February 6, 2026.

Earnings Date	Feb 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Beryl Drugs has 5.07 million shares outstanding. The number of shares has decreased by -0.68% in one year.

Current Share Class	5.07M
Shares Outstanding	5.07M
Shares Change (YoY)	-0.68%
Shares Change (QoQ)	-15.64%
Owned by Insiders (%)	37.85%
Owned by Institutions (%)	n/a
Float	3.15M

Valuation Ratios

The trailing PE ratio is 48.04.

PE Ratio	48.04
Forward PE	n/a
PS Ratio	0.59
PB Ratio	1.19
P/TBV Ratio	1.19
P/FCF Ratio	n/a
P/OCF Ratio	4.68
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.59, with an EV/FCF ratio of -13.04.

EV / Earnings	66.32
EV / Sales	0.81
EV / EBITDA	6.59
EV / EBIT	16.26
EV / FCF	-13.04

Financial Position

The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.45.

Current Ratio	1.40
Quick Ratio	0.73
Debt / Equity	0.45
Debt / EBITDA	1.83
Debt / FCF	-3.61
Interest Coverage	2.58

Financial Efficiency

Return on equity (ROE) is 2.49% and return on invested capital (ROIC) is 4.32%.

Return on Equity (ROE)	2.49%
Return on Assets (ROA)	3.47%
Return on Invested Capital (ROIC)	4.32%
Return on Capital Employed (ROCE)	8.25%
Weighted Average Cost of Capital (WACC)	4.18%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	1.12
Inventory Turnover	4.82

Taxes

In the past 12 months, Beryl Drugs has paid 3.58 million in taxes.

Income Tax	3.58M
Effective Tax Rate	60.49%

Stock Price Statistics

The stock price has decreased by -38.30% in the last 52 weeks. The beta is 0.04, so Beryl Drugs's price volatility has been lower than the market average.

Beta (5Y)	0.04
52-Week Price Change	-38.30%
50-Day Moving Average	22.75
200-Day Moving Average	21.91
Relative Strength Index (RSI)	47.71
Average Volume (20 Days)	844

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Beryl Drugs had revenue of INR 191.97 million and earned 2.34 million in profits. Earnings per share was 0.46.

Revenue	191.97M
Gross Profit	95.02M
Operating Income	9.55M
Pretax Income	5.92M
Net Income	2.34M
EBITDA	23.56M
EBIT	9.55M
Earnings Per Share (EPS)	0.46

Balance Sheet

The company has 668,000 in cash and 43.01 million in debt, with a net cash position of -42.35 million or -8.35 per share.

Cash & Cash Equivalents	668,000
Total Debt	43.01M
Net Cash	-42.35M
Net Cash Per Share	-8.35
Equity (Book Value)	94.69M
Book Value Per Share	21.28
Working Capital	23.23M

Cash Flow

In the last 12 months, operating cash flow was 24.12 million and capital expenditures -36.03 million, giving a free cash flow of -11.90 million.

Operating Cash Flow	24.12M
Capital Expenditures	-36.03M
Free Cash Flow	-11.90M
FCF Per Share	-2.35

Margins

Gross margin is 49.49%, with operating and profit margins of 4.97% and 1.22%.

Gross Margin	49.49%
Operating Margin	4.97%
Pretax Margin	3.09%
Profit Margin	1.22%
EBITDA Margin	12.27%
EBIT Margin	4.97%
FCF Margin	n/a

Dividends & Yields

Beryl Drugs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.68%
Shareholder Yield	0.68%
Earnings Yield	2.07%
FCF Yield	-10.55%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	6